• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Sarah Faulkner

Teva plans competitor for Mylan’s EpiPen

September 12, 2016 By Sarah Faulkner

Teva Pharmaceutical (NYSE:TEVA) said last week that it hopes to win U.S. approval for its version of Mylan‘s (NSDQ:MYL) EpiPen by late 2017 or early 2018. Mylan’s EpiPen holds an estimated 94% market share in the U.S.; an alternate device from Teva could threaten the product’s dominance. Teva’s application for its epinephrine injector has been […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Wall Street Beat Tagged With: Mylan, Teva Pharmaceuticals

Organovo launches bio-printed kidney tissue service

September 9, 2016 By Sarah Faulkner

Organovo (PINK:ONVO), the contract research organization known for their 3D bio-printed liver tissue, announced today that it began commercial contracting for its second tissue service, the ExVive Human Kidney. The San Diego, Calif.-based group is widely recognized for their bio-printed liver tissue that pharma giants like Merck and Roche use to assess toxicity for pre-clinical […]

Filed Under: Biotech Tagged With: Organovo

Chrono Therapeutics closes $48m Series B for smart nicotine patch

September 9, 2016 By Sarah Faulkner

Hayward, Calif.-based startup Chrono Therapeutics reportedly raised $47.6m in a Series B round, led by Kaiser Permanente Ventures. The money, Chrono CEO Alan Levy told Forbes, is to fund clinical trials of a transdermal smoking cessation patch. The company is preparing for a large, Phase II efficacy study of the technology. Unlike normal nicotine patches, Chrono said […]

Filed Under: Digital Health, Drug-Device Combinations, Funding Roundup Tagged With: Chrono Therapeutics

Takeda looks to wearables for IBD patients

September 8, 2016 By Sarah Faulkner

Takeda Pharmaceuticals (TYO:4502) yesterday launched a wearable watch pilot program to help people suffering with inflammatory bowel disease track their symptoms. Takeda said they will roll out the program, iBData, with 100 patients tracking their daily symptoms and lifestyle factors. Then, the data is collected into a report that is shared with the patient’s doctor, […]

Filed Under: Digital Health, Patient Monitoring Tagged With: Takeda Pharmaceuticals

More Respimat data from Boehringer

September 8, 2016 By Sarah Faulkner

Boehringer Ingelheim on Tuesday touted results from the Phase III CanoTinA asthma trial, which showed that adding tiotropium Respimat to maintenance asthma therapy in kids ages 6-11 significantly improves lung function compared to placebo. The results were presented Tuesday at the European Respiratory Society International Congress 2016 in London. This comes 1 day after results from another clinical trial […]

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Boehringer Ingelheim Pharmaceuticals

JDRF backs Sernova’s implant for T1D

September 8, 2016 By Sarah Faulkner

Canadian-based drug device maker Sernova Inc. is working with the Juvenile Diabetes Research Foundation on a clinical trial of Sernova’s cell pouch system to treat hypoglycemia unawareness patients with severe type 1 diabetes. The JDRF will give $2.45 million to support a clinical trial at a transplantation center in the U.S., according to the agreement. Hypoglycemia […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations Tagged With: Juvenile Diabetes Research Foundation (JDRF), Sernova Inc

Senate panel to investigate Mylan’s EpiPen pricing

September 8, 2016 By Sarah Faulkner

The U.S. Senate’s investigations panel is reportedly launching a “preliminary inquiry” into Mylan’s (NSDQ:MYL) pricing of the EpiPen epinephrine auto-injector. Mylan came under fire in recent weeks for raising the price of EpiPens nearly 500%, from $100 in 2008 to more than $500 this year, despite stable manufacturing costs. In late August, Sens. Amy Klobuchar […]

Filed Under: Drug-Device Combinations, Wall Street Beat Tagged With: Capitol Hill, Mylan

DelMar, Accurexa ink deal for chemotherapy combo

September 7, 2016 By Sarah Faulkner

DelMar Pharmaceuticals and Accurexa  said today that they inked a deal to collaborate on a combination chemotherapy for local treatment of brain cancer. The agreement calls for DelMar to supply the drug dianhydrogalactitol (VAL-083) as part of a combination with another chemotherapeutic, either temozolomide or carmustine, for local delivery to the tumor via Accurexa’s ACX-31 implantable […]

Filed Under: Drug-Device Combinations, Neurological, Oncology, Pharmaceutical, Research & Development Tagged With: Accurexa Inc., DelMar Pharmaceuticals

GlaxoSmithKline’s triple combo with Innoviva tops Symbicort Turbohaler in COPD

September 7, 2016 By Sarah Faulkner

GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) yesterday touted results from a Phase III study investigating the triple-combination therapy fluticasone furoate/umeclidnium/vilanterol for patients with chronic obstructive pulmonary disease. The 1,810-patient Fulfil study is a randomized, double-blinded trial comparing once-daily FF/UMEC/VI against AstraZeneca‘s (NYSE:AZN) Symbicort Turbohaler dry powder inhaler, a twice-daily combination of budesonide and formoterol. Patients in the FF/UMEC/VI […]

Filed Under: Clinical Trials, Drug-Device Combinations, Research & Development Tagged With: AstraZeneca plc, GlaxoSmithKline plc, Innoviva

Parents file lawsuit against Mylan over EpiPen ‘price-gouging’

September 7, 2016 By Sarah Faulkner

A parent in Ohio reportedly leveled a class-action lawsuit against EpiPen maker Mylan (NSDQ:MYL) over the nearly 500% increase in the cost of the epinephrine injector since Mylan acquired the device in 2007. The suit, filed yesterday in Hamilton County Common Pleas Court, seeks an unspecified amount of damages for its 25 plaintiffs, according to Cincinnati.com. […]

Filed Under: Drug-Device Combinations, Legal News Tagged With: Mylan

Boehringer Ingelheim touts Stiolto Respimat data

September 6, 2016 By Sarah Faulkner

Boehringer Ingelheim yesterday touted results from a Phase III trial showing that its Stiolto Respimat, a drug-device combination helps people with chronic obstructive pulmonary disease walk for longer periods of time while relieving some shortness of breath. When participants with moderate to severe COPD took Stiolto Respimat, a combination of tiotropium bromide and olodaterol, along […]

Filed Under: Clinical Trials, Drug-Device Combinations, Respiratory Tagged With: Boehringer Ingelheim Pharmaceuticals

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 250
  • Go to page 251
  • Go to page 252

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS